New Age Alpha Advisors LLC Decreases Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Key Points

• New Age Alpha Advisors LLC cut its stake in Ascendis Pharma A/S by 53.2%, reducing their holdings to 1,721 shares valued at approximately $268,000.
• Several institutional investors, including Point72 Asia and Tower Research Capital, have made notable purchases or increased their holdings in Ascendis Pharma during the fourth quarter.
• Ascendis Pharma reported $216.28 million in revenue for the last quarter, surpassing analysts' expectations of $163.17 million, while earnings per share (EPS) came in at ($0.93), beating estimates of ($1.42).

New Age Alpha Advisors LLC lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 53.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,721 shares of the biotechnology company's stock after selling 1,959 shares during the quarter. New Age Alpha Advisors LLC's holdings in Ascendis Pharma A/S were worth $268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of ASND. T. Rowe Price Investment Management Inc. raised its position in shares of Ascendis Pharma A/S by 54.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after purchasing an additional 960,504 shares during the last quarter. Capital International Investors raised its position in shares of Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after purchasing an additional 753,859 shares during the last quarter. RA Capital Management L.P. raised its position in shares of Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the last quarter. Vestal Point Capital LP raised its position in Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock worth $71,588,000 after buying an additional 270,000 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Ascendis Pharma A/S by 4.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after buying an additional 193,688 shares during the last quarter.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND traded up $0.01 during mid-day trading on Tuesday, reaching $195.98. 803,613 shares of the company traded hands, compared to its average volume of 535,961. The company's 50 day moving average price is $174.87 and its 200-day moving average price is $160.01. The firm has a market cap of $11.98 billion, a PE ratio of -37.98 and a beta of 0.41. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Cantor Fitzgerald boosted their target price on Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research report on Friday. Stifel Nicolaus boosted their target price on Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a "buy" rating in a research report on Friday. Evercore ISI boosted their target price on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Wall Street Zen raised Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Bank of America boosted their target price on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. Seventeen investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of "Buy" and an average price target of $239.80.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.